These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37143124)

  • 1. Echinomycin as a promising therapeutic agent against KSHV-related malignancies.
    Chen J; Lin Z; Song J; Plaisance-Bonstaff K; James J; Mu S; Post SR; Dai L; Qin Z
    J Hematol Oncol; 2023 May; 16(1):48. PubMed ID: 37143124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of KAP1 enhances hypoxia-induced Kaposi's sarcoma-associated herpesvirus reactivation through RBP-Jκ.
    Zhang L; Zhu C; Guo Y; Wei F; Lu J; Qin J; Banerjee S; Wang J; Shang H; Verma SC; Yuan Z; Robertson ES; Cai Q
    J Virol; 2014 Jun; 88(12):6873-84. PubMed ID: 24696491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
    Paul AG; Chandran B; Sharma-Walia N
    Transl Res; 2013 Aug; 162(2):77-92. PubMed ID: 23567332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.
    Wood JJ; Boyne JR; Paulus C; Jackson BR; Nevels MM; Whitehouse A; Hughes DJ
    J Virol; 2016 Oct; 90(20):9543-55. PubMed ID: 27512077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
    Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
    J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
    Yeh WW; Chen YQ; Yang WS; Hong YC; Kao S; Liu TT; Chen TW; Chang L; Chang PC
    J Virol; 2022 Aug; 96(16):e0075522. PubMed ID: 35914074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research].
    Watanabe T; Fujimuro M
    Yakugaku Zasshi; 2019; 139(1):69-73. PubMed ID: 30606932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycolysis, Glutaminolysis, and Fatty Acid Synthesis Are Required for Distinct Stages of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication.
    Sanchez EL; Pulliam TH; Dimaio TA; Thalhofer AB; Delgado T; Lagunoff M
    J Virol; 2017 May; 91(10):. PubMed ID: 28275189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Expression and Nuclear Retention Element of Polyadenylated Nuclear RNA Is Not Required for Productive Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.
    Gutierrez IV; Dayton J; Harger S; Rossetto CC
    J Virol; 2021 Jun; 95(13):e0009621. PubMed ID: 33853955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target.
    Hughes DJ; Wood JJ; Jackson BR; Baquero-Pérez B; Whitehouse A
    PLoS Pathog; 2015 Mar; 11(3):e1004771. PubMed ID: 25794275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi's Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-κB-Signaling Axis.
    Yan Q; Zhao R; Shen C; Wang F; Li W; Gao SJ; Lu C
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FoxO1 Suppresses Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication and Controls Viral Latency.
    Gao R; Li T; Tan B; Ramos da Silva S; Jung JU; Feng P; Gao SJ
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30404794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis.
    Mesri EA; Cavallin LE; Ashlock BM; Leung HJ; Ma Q; Goldschmidt-Clermont PJ
    Immunol Res; 2013 Dec; 57(1-3):159-65. PubMed ID: 24203444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirtuin 6 Attenuates Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Suppressing Ori-Lyt Activity and Expression of RTA.
    Hu M; Armstrong N; Seto E; Li W; Zhu F; Wang PC; Tang Q
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by 5'-AMP-Activated Protein Kinase.
    Cheng F; He M; Jung JU; Lu C; Gao SJ
    J Virol; 2016 Jul; 90(14):6515-6525. PubMed ID: 27147746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of KSHV Latency and Lytic Reactivation.
    Broussard G; Damania B
    Viruses; 2020 Sep; 12(9):. PubMed ID: 32957532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.
    Chen J; Dai L; Goldstein A; Zhang H; Tang W; Forrest JC; Post SR; Chen X; Qin Z
    PLoS Pathog; 2019 Dec; 15(12):e1008156. PubMed ID: 31790497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.
    Katano H
    Adv Exp Med Biol; 2018; 1045():357-376. PubMed ID: 29896675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use.
    Beauclair G; Naimo E; Dubich T; Rückert J; Koch S; Dhingra A; Wirth D; Schulz TF
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31826996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.